ENTPD3

Across TCGA pan-cancer cohorts, ENTPD3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENTPD3 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ENTPD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ENTPD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where ENTPD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.777	0.583	.018	8	view →
HNSC	DFS	Median	All	0.985	0.898	.010	4	view →
LUAD	OS	Tertile	II,III,IV	0.363	0.869	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ENTPD3–LSCC (DFS)

Open the LSCC breakdown →